Immunome director buys 5,000 shares in open market

Immunome Inc. director Jean Jacques Bienaime bought additional shares of the company’s stock.

Rhea-AI Filing Summary

Immunome Inc. director Jean Jacques Bienaime bought additional shares of the company’s stock. On May 15, 2026, he made an open-market purchase of 5,000 shares of Immunome common stock at a weighted average price of $20.70 per share.

The filing notes that individual trade prices ranged from $20.645 to $20.72 per share. Following this transaction, Bienaime directly holds 43,415 shares of Immunome common stock, reflecting a modest increase in his personal stake.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider BIENAIME JEAN JACQUES

Role Director

Bought 5,000 shs ($104K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$20.70	$104K

Holdings After Transaction: Common Stock — 43,415 shares (Direct)

Footnotes (1)

1. F1. The weighted average purchase price for the transaction report was $20.70, and the range of prices were between $20.645 and $20.72, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

Key Figures

Shares purchased: 5,000 shares Weighted average price: $20.70 per share Post-transaction holdings: 43,415 shares +3 more

6 metrics

Shares purchased 5,000 shares Open-market buy on May 15, 2026

Weighted average price $20.70 per share Price for 5,000-share purchase

Post-transaction holdings 43,415 shares Shares directly owned after trade

Trade price range low $20.645 per share Lowest price in reported purchase range

Trade price range high $20.72 per share Highest price in reported purchase range

Net buy shares 5,000 shares Net change in non-derivative position from Form 4

Key Terms

open-market purchase, weighted average purchase price, Common Stock

3 terms

open-market purchase financial

"he made an open-market purchase of 5,000 shares of Immunome common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The weighted average purchase price for the transaction report was $20.70"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

Common Stock financial

"open-market purchase of 5,000 shares of Immunome common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Immunome (IMNM) report for Jean Jacques Bienaime?

Immunome reported that director Jean Jacques Bienaime made an open-market purchase of 5,000 shares of the company’s common stock. The transaction increased his direct holdings and was executed at a weighted average price of $20.70 per share.

How many Immunome (IMNM) shares did the director buy and at what price?

The director purchased 5,000 shares of Immunome common stock at a weighted average price of $20.70 per share. Trade prices for this transaction ranged from $20.645 to $20.72, according to the disclosure footnote.

What are Jean Jacques Bienaime’s Immunome (IMNM) holdings after this Form 4 transaction?

After the reported open-market purchase, Jean Jacques Bienaime directly holds 43,415 shares of Immunome common stock. This reflects his position immediately following the 5,000-share acquisition disclosed in the Form 4 filing.

Was the Immunome (IMNM) insider trade an open-market purchase or another type of transaction?

The transaction was classified as an open-market purchase of common stock. The Form 4 identifies it with code P, meaning shares were bought on the market or in a private transaction rather than issued as compensation or through option exercises.

What price range did the Immunome (IMNM) insider use to buy shares?

The filing states that the weighted average purchase price was $20.70 per share, with individual trades executed between $20.645 and $20.72. Detailed price and share breakdowns are available upon request from the company or the SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 07:56 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		P		5,000	A	$20.7(1)	43,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average purchase price for the transaction report was $20.70, and the range of prices were between $20.645 and $20.72, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

	/s/ Sandra Stoneman, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)